The article by Hoos et al. (1) in this issue of the Journal makes three recommendations about endpoints in immunotherapy trials: 1) cellular immune response assays are highly variable and require standardization; 2) immunotherapies may evince unusual patterns of antitumor response and therefore require different endpoints; and 3) immunotherapy may have a delayed benefit on survival, which requi...